Bracco Bolsters AI Imaging Portfolio with EU Launch, Avicenna.AI Partnership
Event summary
- Bracco Imaging launched AiMIFY®, an AI-powered contrast enhancement software, in the European Union, developed in collaboration with Subtle Medical.
- Bracco entered a strategic co-development and commercial partnership with Avicenna.AI to advance AI applications in contrast-enhanced computed tomography (CT).
- The Avicenna.AI collaboration will focus on computer-aided detection and diagnosis in brain CT angiography, with FDA submission anticipated in 2H 2026.
- Both initiatives will be showcased at the 2026 European Congress of Radiology (ECR).
The big picture
Bracco’s moves signal a broader trend of established medical device and pharmaceutical companies aggressively integrating AI to enhance diagnostic capabilities and streamline workflows. This partnership allows Bracco to expand beyond its core contrast agent business and compete more directly in the rapidly evolving AI-driven medical imaging market. The focus on CT angiography suggests a targeted approach to address a specific clinical need and potentially capture a significant share of a growing market.
What we're watching
- Regulatory Approval
- The timing and scope of the FDA submission for the Avicenna.AI CT applications will be a key indicator of the partnership’s progress and potential market entry in the US.
- Integration Risk
- Successful integration of Avicenna.AI’s interpretative AI into Bracco’s existing workflow and product portfolio will be crucial for realizing the partnership’s strategic benefits.
- Competitive Response
- How competitors in the diagnostic imaging space, particularly those with existing AI capabilities, will react to Bracco’s expanded AI offerings warrants close observation.
Related topics